Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharma Strikes Out At Supreme Court As Three Recent Cert Petitions Fail

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer, Cephalon and former InterMune CEO Scott Harkonen will find no relief from the high court.


Related Content

Regeneron's Patent Pratfall: First Inequitable Conduct, Now Possible Sanctions
Appeals Court Revives RICO Off-Label Suit Against Abbott
Off-Label Is Off The Docket: Supreme Court Leaves RU-486 Flexibility Intact
Pfizer Litigation Strategy: Business Focus, Legal Alliance Drive Successes
Takeda False Claim Act Case May Allow Supreme Court To Set Evidence Threshold
PhRMA Offers “No Reasonable Expert” Standard For Addressing Fraud Charges
Former InterMune CEO Sentenced To Probation, DoJ Reindicts Former GSK Attorney
Pfizer Must Pay Kaiser Cost-Difference Of Cheaper Drugs Under Neurontin Marketing Ruling


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts